Spyre Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a clinical-stage biotechnology company pioneering long-acting antibodies and rational antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's pipeline is built around three validated biological targets: α4β7 integrin (SPY001), TL1A (SPY002 and SPY072), and IL-23 (SPY003). By utilizing advanced antibody engineering, such as half-life extension technologies, Spyre aims to deliver therapeutics with superior efficacy and highly convenient dosing schedules (e.g., quarterly or biannual subcutaneous maintenance dosing) compared to existing first-generation biologics.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A master-protocol Phase 2 platform trial evaluating Spyre's core monotherapies (SPY001, SPY002, SPY003) and pairwise combination therapies (SPY120, SPY130, SPY230) in patients with moderately to severely active ulcerative colitis.
Expected impact: Aims to identify optimized monotherapy and combination regimens that deliver superior efficacy, safety, and convenient quarterly or twice-yearly dosing profiles.
A Phase 2 basket trial evaluating SPY072 (an extended half-life anti-TL1A antibody) across three distinct rheumatologic indications: rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
Expected impact: Expands Spyre's pipeline beyond inflammatory bowel disease into large, high-unmet-need rheumatic disease markets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Aeglea BioTherapeutics acquired private Spyre Therapeutics in a stock-for-stock reverse merger transaction. This transformational deal shifted the combined company's focus entirely to Spyre's pipeline of long-acting antibodies for inflammatory bowel disease, leading to a corporate renaming to Spyre Therapeutics, Inc. (NASDAQ: SYRE).
Financial impact: Functionally remade the company, providing immediate access to public capital markets and securing concurrent private placement (PIPE) funding of $210 million.
Strategic Partnerships
High. Paragon is the discovery engine behind Spyre's core pipeline. Under the agreement, Spyre holds exclusive global licenses to develop and commercialize antibody products discovered using Paragon's proprietary technology, including SPY001, SPY002, SPY003, and SPY072.
Terms: Spyre compensates Paragon for research services and is obligated to pay potential development, regulatory, and clinical milestones (e.g., up to $22.0 million for SPY003), alongside low single-digit royalties on net sales.